Starpharma Holdings Limited · ASX:SPL
Starpharma — ASCO 2024 Annual Meeting
13 slides from Starpharma's conference presentation, Jun 4, 2024
Slide 1: DEP irinotecan presentation at ASCO 2024 Annual Meeting
ASX Announcement DEP® irinotecan presentation at ASCO 2024 Annual Meeting Melbourne, Australia; 4 June 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US.
Slide 2: About Starpharma
About Starpharma Starpharma (ASX: SPL, OTCQX: SPHRY) is dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanos
Slide 3: Dendrimer-enhanced (DEP) SN38 in patients with advanced solid tumors: a Phase 1/2 trial
3rd June 2024, 8:00-9:30 am Dendrimer-enhanced (DEP) SN38 For personal use only (DEP irinotecan) in patients with advanced solid tumors: a Phase 1/2 trial Jia (Jenny) Liu1, Anna R. Minchom2, Alastair Greystoke3, Thomas R.J. Evans4, Debashis Sarker5, Anthony M. Joshua1, Cienne Morton5, Burak Aktas5,
Slide 4: Summary
2 Summary Results from DEP SN38 Phase 1/2 clinical trial in 114 patients with advanced solid tumors: For personal use only 1. Dendrimer technology has potential to deliver a range of DEP SN38 dendrimer payloads with improved safety / efficacy nanoparticle Linker 2. DEP SN38 (12.5 mg/m2) well-tolerat
Slide 5: DEP SN38 Dendrimer Nanoparticle Mechanism
DEP SN38 Dendrimer Nanoparticle Mechanism DEP SN38 dendrimer nanoparticle • 3D-poly-lysine dendrimers act as scaffold for delivery of a range of payloads, including cytotoxics1 Linker • DEP SN38 does not require liver metabolism for conversion into active SN38 For personal use only PEG metabolite
Slide 6: Study Design DEP SN38 Phase 1/2 Clinical Trial
4 Study Design DEP SN38 Phase 1/2 Clinical Trial • Multicenter first-in-human open-label For personal use only trial1,2 MONOTHERAPY COMBINATION DEP SN38 DEP SN38 + 5-FU/LV • DEP SN38 administered IV q3wkly or q2wkly infusion without corticosteroid/atropine pre-medication Q3W P1a Dose Escalation Q2W
Slide 7: Patient Characteristics – All Treated Patients
5 Patient Characteristics – All Treated Patients BASELINE CHARACTERISTICS COLORECTAL OVARIAN PANCREATIC BREAST OTHER1 TOTAL Subjects enrolled (n, %) 55 (48%) 23 (20%) 15 (13%) 8 (7%) 13 (11%) 114 (100%) For personal use only Subjects ongoing (n, %) 4 (7%) 2 (9%) 0 (0%) 0 (0%) 0 (0%) 6 (5%) Median 59
Slide 8: DEP SN38 Safety and Tolerability
DEP SN38 Safety and Tolerability DEP SN38 is well-tolerated with a notable lack of severe GI toxicity and mostly mild/moderate AEs For personal use only RP2D 12.5 mg/m2 for Q2W and Q3W Treatment-related AEs in ≥10% patients (N=114) Dose Level / Regimen DLT Non-hematological AEs Hematological / Lab A
Slide 9: CRC Efficacy Overview
Best % Change in Sum of Target Lesion Size (RECIST 1.1) CRC Combination Therapy CRC Efficacy Overview 40 30 34 (n=14) PR % change (nadir vs baseline) 20 SD 6 PD 10 1 1 Efficacy Response 0 For personal use only Median number of prior lines -10 4 (2-9) -8 -11 -12 -12 -13 -13 (range) -20 RECIST 1.1 Eva
Slide 10: Ovarian Efficacy Overview
CA-125 biomarker reduced in >75% patients - up to 98% ↓8 Ovarian Efficacy Overview 60 40 36 CA-125 Best change from baseline (%) 23 19 20 2 Total Q2W Q3W 0 Efficacy Response (n=23) (n=8) (n=15) For personal use only -20 Median prior lines (range) 6 (3-9) 6 (4-8) 6 (3-9) -40 -29 -29 -30 -34 DEP SN38
Slide 11: Key Points
9 Key Points Dendrimer nanoparticles offer a better way to deliver chemotherapy, focusing the treatment on cancer cells and sparing healthy tissue, helping to improve effectiveness and reduce side effects For personal use only DEP SN38 dendrimer Nausea 1.8% 68.4% Monotherapy nanoparticle DCR 48% Alo
Slide 12: Future Directions
10 Future Directions • Confirm efficacy of DEP SN 38 vs irinotecan in randomized trials For personal use only • Explore synergy of DEP SN38 in combination with checkpoint / PARP inhibition • Dendrimer platform to improve efficacy and safety profile of different payloads PRESENTED BY: Dr Jia (Jenny)
Slide 13: Acknowledgements
11 Acknowledgements For personal use only • Patients and their caregivers • All investigators, co-investigators and site support staff who conducted this trial • Sponsor: Starpharma Pty Ltd PRESENTED BY: Dr Jia (Jenny) Liu, MD PhD FRACP